


Ask a doctor about a prescription for INVOKANA 100 mg FILM-COATED TABLETS
Patient Information: Summary of Product Characteristics
Invokana 100 mg film-coated tablets
Invokana 300 mg film-coated tablets
canagliflozin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Invokana contains the active substance canagliflozin, which belongs to a group of medicines called “oral anti-hyperglycaemics”.
Invokana is used:
This medicine works by removing more sugar from your body through urine. This reduces the amount of sugar in your blood and can help prevent heart disease in patients with type 2 diabetes mellitus (T2DM). It also helps to delay the worsening of kidney function in patients with T2DM through a mechanism that goes beyond the reduction of blood glucose levels.
Invokana is given as monotherapy or in combination with other medicines that you may already be taking to treat your type 2 diabetes (such as metformin, insulin, a DPP-4 inhibitor [such as sitagliptin, saxagliptin, or linagliptina], a sulfonylurea [such as glimepiride or glipizide], or pioglitazone) that lower blood sugar levels. You may already be taking one or more of these medicines to treat your type 2 diabetes.
It is important that you do not stop following the advice of your doctor or nurse about diet and exercise.
What is type 2 diabetes?
Type 2 diabetes is a disorder in which your body does not make enough insulin and the insulin it does make does not work well. It can also be that your body makes too much sugar.
When this happens, sugar (glucose) builds up in your blood. This can cause serious medical problems, such as heart disease, kidney disease, blindness, and amputations.
Do not take Invokana:
if you are allergic to canagliflozin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before and during treatment with Invokana:
If any of the above situations apply to you (or if you are unsure), talk to your doctor, pharmacist, or nurse before taking this medicine.
Kidney function
You will have a kidney check through a blood test before starting and while taking this medicine.
Glucose in urine
Due to how this medicine works, your urine will test positive for sugar (glucose) while taking this medicine.
Children and adolescents
Invokana is not recommended for children and adolescents under 18 years of age.
Other medicines and Invokana
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This medicine may affect how other medicines work. Also, other medicines may affect how this medicine works.
In particular, tell your doctor if you are taking any of the following medicines:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Invokana should not be used during pregnancy. Ask your doctor about the best way to stop taking Invokana and control your blood sugar levels as soon as you know you are pregnant.
You should not take this medicine if you are breast-feeding. Ask your doctor if you should stop taking this medicine or stop breast-feeding.
Driving and using machines
Invokana has no or negligible influence on the ability to drive and use machines. However, some patients may experience dizziness or drowsiness, which may affect their ability to drive, ride a bicycle, or use tools or machines.
Taking Invokana with other diabetes medicines called sulfonylureas (such as glimepiride or glipizide) or insulin may increase the risk of low blood sugar levels (hypoglycemia). Symptoms include blurred vision, tingling of the lips, tremor, sweating, pallor, mood change, anxiety, or confusion. All these may affect your ability to drive, ride a bicycle, or use tools or machines. Tell your doctor as soon as possible if you have any symptoms of low blood sugar.
Invokana contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Invokana contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
How much to take
When taking this medicine
Your doctor may prescribe Invokana with another anti-diabetic medicine.
Remember to take all your medicines as instructed by your doctor to get the best results for your health.
Diet and exercise
To control your diabetes, you still need to follow the advice of your doctor, pharmacist, or nurse about diet and exercise. In particular, if you follow a weight-control diet, you should continue it while taking this medicine.
If you take more Invokana than you should
If you take more medicine than you should, talk to your doctor or go immediately to the nearest hospital.
If you forget to take Invokana
If you stop taking Invokana
Your blood sugar levels may increase if you stop taking this medicine. Do not stop taking this medicine without talking to your doctor first.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Invokana and talk to a doctor or go immediately to the nearest hospital if you experience any of the following serious side effects:
Severe allergic reaction (rare, may affect up to 1 in 1,000 people)
Possible symptoms of a severe allergic reaction may include:
Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)
These are symptoms of diabetic ketoacidosis (see also section 2):
This can occur regardless of your blood sugar levels. Diabetic ketoacidosis can occur more frequently as kidney function worsens. Your doctor may decide to stop your treatment with Invokana temporarily or permanently.
Dehydration (uncommon, may affect up to 1 in 100 people)
Possible symptoms of dehydration are:
Tell your doctor as soon as possible if you experience any of the following side effects:
Hypoglycemia (very common, may affect more than 1 in 10 people)
Possible symptoms of low blood sugar are:
Your doctor will explain how to treat low blood sugar levels and what to do if you have any of the above symptoms.
Urinary tract infections (common, may affect up to 1 in 10 people)
Although uncommon, if you notice blood in your urine, tell your doctor immediately.
Other side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. The expiry date refers to the last day of the month indicated.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice visible signs of deterioration or tampering.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Invokana
Appearance and Package Contents of the Product
Invokana is available in precut unit-dose blisters of PVC/aluminum. The pack sizes are cardboard boxes of 10 x 1, 30 x 1, 90 x 1, or 100 x 1 tablets.
Only some pack sizes may be marketed.
Marketing Authorisation Holder
Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italy
You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien Menarini Benelux NV/SA Tél/Tel: +32 (0)2 721 4545 | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 |
| Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: +32 (0)2 721 4545 |
Ceská republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 | Magyarország Janssen‑Cilag Kft. Tel.: +36 1 884 2858 |
Danmark Berlin-Chemie AG Tlf: +45 78 71 31 21 | Malta AM MANGION LTD Tel: +356 2397 6000 |
Deutschland Janssen‑Cilag GmbH Tel: 0800 086 9247 / +49 2137 955 6955 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 | Norge Berlin-Chemie AG Tlf: +45 78 71 31 21 |
Ελλ?δα MENARINI HELLAS AE Tηλ: +30 210 8316111-13 | Österreich
Tel: +43 1 879 95 85-0 |
España Laboratorios Menarini, S.A. Tel: +34 93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal
Tel: +351 210 935 500 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland A.Menarini Pharmaceuticals Ireland Ltd Tel: +353 1 284 6744 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Ísland Janssen‑Cilag AB c/o Vistor hf. Sími: +354 535 7000 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2 544 30 730 |
Italia Laboratori Guidotti S.p.A. Tel: +39 050 971011 | Suomi/Finland Berlin-Chemie/A. Menarini Suomi Oy Puh/Tel: +358 403 000 760 |
Κ?προς MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Sverige Berlin-Chemie AG Tfn: +45 78 71 31 21 |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 | United Kingdom (Northern Ireland)
Tel: +44 (0)1628 856400 |
Date of last revision of this leaflet: September 2024.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of INVOKANA 100 mg FILM-COATED TABLETS in October, 2025 is around 51.52 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for INVOKANA 100 mg FILM-COATED TABLETS – subject to medical assessment and local rules.